Sapience Therapeutics Announces Oral Presentation at the Upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Featuring Lucicebtide Phase 2 Results
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that data from...